Table 5.
Comparisons of daily insulin dosage change from baseline in different treatment groups
| No. studies | No. participants (active agents vs PBO) | WMD from baseline | 95% CI | P‐value | |
|---|---|---|---|---|---|
| Daily insulin dosage change from baseline (U/day) | |||||
| DPP‐4i/INS | 4 | 1,307/1,154 | −2.17 | −3.18, −1.15 | <0.01a |
| AGI/INS | 2 | 142/141 | 0.28 | −2.85, 3.40 | 0.86 |
| TZD/INS | 5 | 518/524 | −16.15 | −25.89, −6.42 | <0.01a |
| SGLT‐2i/INS | 3 | 545/490 | −6.00 | −12.28, 0.27 | 0.06 |
| GLP‐1RA/INS | 7 | 1,393/1,223 | −3.39 | −4.74, −2.04 | <0.01a |
a
P‐value < 0.05. AGI, alpha‐glucosidase inhibitors; CI, confidence interval; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated hemoglobin; INS, insulin; PBO, placebo; SGLT‐2i, sodium–glucose cotransporter 2 inhibitor; TZD, thiazolidinediones; U, unit; WMD, weighted mean difference.